Abstract
A series of triazolo-pyridazinone derivatives were prepared through the standard click reactions of 4,6-diphenyl-2-(prop-2-yn-1-yl)pyridazin-3(2H)-one 1, possessing a free terminal alkyne group with a selection of substituted aryl azides 2-9. The cytotoxicity and in vitro anticancer investigation of the new compounds were conducted against four different human tumor cell lines, including breast adenocarcinoma MCF-7, hepatocellular carcinoma HepG2, lung cancer A549 and colon cancer HCT116 cell lines. The results showed that the compounds exerted their actions in MCF-7 and A549 via inhibition of the urokinase activity. The compound 17 showed potent anticancer activity compared with the activity of the standard anticancer drug, doxorubicin. Molecular docking studies were performed to support the activity data and predict the plausible mechanisms of the ligand-protein interactions.
Keywords: Trizolo-pyridazinone, anticancer, urokinase, MCF-7, HepG2, A549, HCT116.
Graphical Abstract
Current Organic Chemistry
Title:Click Synthesis, Anticancer Activity and Molecular Docking Studies on Pyridazinone Scaffolds
Volume: 22 Issue: 23
Author(s): Tamer El Malah*, Hany F. Nour, Oussama Dehbi, Farouk M.E. Abdel-Megeid, Abeer Essam El-Din Mahmoud, Mamdouh Moawad Ali and Salwa M. Soliman
Affiliation:
- National Research Centre, Chemical Industries Research Division, Photochemistry Department, 33 El Buhouth Street, P.O. Box 12622, Giza,Egypt
Keywords: Trizolo-pyridazinone, anticancer, urokinase, MCF-7, HepG2, A549, HCT116.
Abstract: A series of triazolo-pyridazinone derivatives were prepared through the standard click reactions of 4,6-diphenyl-2-(prop-2-yn-1-yl)pyridazin-3(2H)-one 1, possessing a free terminal alkyne group with a selection of substituted aryl azides 2-9. The cytotoxicity and in vitro anticancer investigation of the new compounds were conducted against four different human tumor cell lines, including breast adenocarcinoma MCF-7, hepatocellular carcinoma HepG2, lung cancer A549 and colon cancer HCT116 cell lines. The results showed that the compounds exerted their actions in MCF-7 and A549 via inhibition of the urokinase activity. The compound 17 showed potent anticancer activity compared with the activity of the standard anticancer drug, doxorubicin. Molecular docking studies were performed to support the activity data and predict the plausible mechanisms of the ligand-protein interactions.
Export Options
About this article
Cite this article as:
El Malah Tamer*, Nour F. Hany , Dehbi Oussama, Abdel-Megeid M.E. Farouk , Mahmoud Essam El-Din Abeer , Ali Moawad Mamdouh and Soliman M. Salwa, Click Synthesis, Anticancer Activity and Molecular Docking Studies on Pyridazinone Scaffolds, Current Organic Chemistry 2018; 22 (23) . https://dx.doi.org/10.2174/1385272822666181029111943
DOI https://dx.doi.org/10.2174/1385272822666181029111943 |
Print ISSN 1385-2728 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5348 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting the Lung: Preclinical and Comparative Evaluation of Anticancer Aerosols in Dogs with Naturally Occurring Cancers
Current Cancer Drug Targets Anti-Cancer Properties of Nigella spp. Essential Oils and their Major Constituents, Thymoquinone and β-Elemene
Current Clinical Pharmacology Editorial [Hot Topic: Recent Advances in Understanding of Cigarette Smoke Free Radicals and Their Relationship to Smoking Related Diseases (Guest Editors: Chuan Liu and Kevin McAdam)]
Mini-Reviews in Organic Chemistry Molecular Mechanisms of Pancreatic Cancer Dissemination: The Role of the Chemokine System
Current Pharmaceutical Design The Role of Glycogen Synthase Kinase-3β in Normal Haematopoiesis, Angiogenesis and Leukaemia
Current Medicinal Chemistry Molecular Pathophysiology of Cavernous Nerve Injury and Identification of Strategies for Nerve Function Recovery After Radical Prostatectomy
Current Drug Targets Inflammatory Cytokines Pathways as Potential Therapeutic Targets for Gastric Cancer
Current Cancer Therapy Reviews From Target Therapy to miRNA Therapeutics of Human Multiple Myeloma: Theoretical and Technological Issues in the Evolving Scenario
Current Drug Targets Histone Lysine-Specific Methyltransferases and Demethylases in Carcinogenesis: New Targets for Cancer Therapy and Prevention
Current Cancer Drug Targets Painting the Target Around the Arrow: Two-Step Prodrug Therapies from a Carbohydrate Chemists Perspective
Current Drug Delivery Gene Therapy in Fanconi Anemia: A Matter of Time, Safety and Gene Transfer Tool Efficiency
Current Gene Therapy The Association of Sleep Disorders, Obesity and Sleep-Related Hypoxia with Cancer
Current Genomics Paclitaxel (Taxol) and Taxoid Derivates for Lung Cancer Treatment: Potential for Aerosol Delivery
Current Cancer Drug Targets iPSCs Derived from Malignant Tumor Cells: Potential Application for Cancer Research
Current Stem Cell Research & Therapy Synthetic Optimization of Ellipticine and Antitumor Activity of Novel Hexacyclic Derivatives of Ellipticine
Current Pharmaceutical Design Controlling Receptor Downregulation by Ubiquitination and Deubiquitination
Current Drug Discovery Technologies How Recent Advances in High-risk Myelodysplastic Syndrome Physiopathology May Impact Future Treatments
Current Pharmaceutical Design The Radionuclide Molecular Imaging and Therapy of Neuroendocrine Tumors
Current Cancer Drug Targets Acrylamide Induced Toxicity and the Propensity of Phytochemicals in Amelioration: A Review
Central Nervous System Agents in Medicinal Chemistry A Mechanistic Overview on Male Infertility and Germ Cell Cancers
Current Pharmaceutical Design